Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Effects of nalfurafine on the reinforcing, thermal antinociceptive, and respiratory-depressant effects of oxycodone: modeling an abuse-deterrent opioid analgesic in rats

Effects of nalfurafine on the reinforcing, thermal antinociceptive, and respiratory-depressant... Psychopharmacology (2017) 234:2597–2605 DOI 10.1007/s00213-017-4652-3 ORIGINAL INVESTIGATION Effects of nalfurafine on the reinforcing, thermal antinociceptive, and respiratory-depressant effects of oxycodone: modeling an abuse-deterrent opioid analgesic in rats 1,2 3 4 5 E. Andrew Townsend & Jennifer E. Naylor & S. Stevens Negus & Shelley R. Edwards & 5 6 7,8 Hina N. Qureshi & Hunter W. McLendon & Christopher R. McCurdy & 7 9 9 9 Coco N. Kapanda & Jussara M. do Carmo & Fernanda S. da Silva & John E. Hall & 10 2 Kenneth J. Sufka & Kevin B. Freeman Received: 18 April 2017 /Accepted: 19 May 2017 /Published online: 31 May 2017 Springer-Verlag Berlin Heidelberg 2017 Abstract effect functions were each determined for oxycodone, Rationale Strategies to reduce the misuse of mu opioid ago- nalfurafine, and the same oxycodone/nalfurafine mixture pro- nists are critically needed. Previous work has shown that kap- portions. Finally, the respiratory-depressant effects of equi- pa opioid agonists can diminish the abuse-related effects and antinociceptive doses of oxycodone, nalfurafine, and the mix- augment the antinociceptive effects of mu agonists. However, tures were compared. use of traditional kappa agonists is limited by their dysphoric Results Nalfurafine decreased the reinforcing effects of oxy- side http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Psychopharmacology Springer Journals

Effects of nalfurafine on the reinforcing, thermal antinociceptive, and respiratory-depressant effects of oxycodone: modeling an abuse-deterrent opioid analgesic in rats

Download PDF
9 pages

Loading next page...
 
/lp/springer_journal/effects-of-nalfurafine-on-the-reinforcing-thermal-antinociceptive-and-F1d6PeGeko
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer-Verlag Berlin Heidelberg
Subject
Biomedicine; Neurosciences; Pharmacology/Toxicology; Psychiatry
ISSN
0033-3158
eISSN
1432-2072
DOI
10.1007/s00213-017-4652-3
pmid
28567699
Publisher site
See Article on Publisher Site

Abstract

Psychopharmacology (2017) 234:2597–2605 DOI 10.1007/s00213-017-4652-3 ORIGINAL INVESTIGATION Effects of nalfurafine on the reinforcing, thermal antinociceptive, and respiratory-depressant effects of oxycodone: modeling an abuse-deterrent opioid analgesic in rats 1,2 3 4 5 E. Andrew Townsend & Jennifer E. Naylor & S. Stevens Negus & Shelley R. Edwards & 5 6 7,8 Hina N. Qureshi & Hunter W. McLendon & Christopher R. McCurdy & 7 9 9 9 Coco N. Kapanda & Jussara M. do Carmo & Fernanda S. da Silva & John E. Hall & 10 2 Kenneth J. Sufka & Kevin B. Freeman Received: 18 April 2017 /Accepted: 19 May 2017 /Published online: 31 May 2017 Springer-Verlag Berlin Heidelberg 2017 Abstract effect functions were each determined for oxycodone, Rationale Strategies to reduce the misuse of mu opioid ago- nalfurafine, and the same oxycodone/nalfurafine mixture pro- nists are critically needed. Previous work has shown that kap- portions. Finally, the respiratory-depressant effects of equi- pa opioid agonists can diminish the abuse-related effects and antinociceptive doses of oxycodone, nalfurafine, and the mix- augment the antinociceptive effects of mu agonists. However, tures were compared. use of traditional kappa agonists is limited by their dysphoric Results Nalfurafine decreased the reinforcing effects of oxy- side

Journal

Psychopharmacology – Springer Journals

Published: May 31, 2017

References

  • Low efficacy opioids: implications for sex differences in opioid antinociception
    Barrett, AC
  • Activation of the brain melanocortin system is required for leptin-induced modulation of chemorespiratory function
    Bassi, M; Nakamura, NB; Furuya, WI; Colombari, DS; Menani, JV; Carmo, JM; Silva, AA; Hall, JE; Colombari, E
  • Effects of the kappa-opioid receptor agonist U-50,488 on morphine-induced place preference conditioning in the developing rat
    Bolanos, CA; Garmsen, GM; Clair, MA; McDougall, SA
  • Kappa-opioid receptor signaling and brain reward function
    Bruijnzeel, AW
  • Biased agonism at kappa opioid receptors: implication in pain and mood disorders
    Dogra, S; Yadav, PN
  • Adverse effects of opioid analgesic drugs
    Duthie, DJ; Nimmo, WS
  • Assessment of the kappa opioid agonist, salvinorin a, as a punisher of drug self-administration in monkeys
    Freeman, KB; Naylor, JE; Prisinzano, TE; Woolverton, WL
  • Blockade of morphine reward through the activation of kappa-opioid receptors in mice
    Funada, M; Suzuki, T; Narita, M; Misawa, M; Nagase, H
  • Kappa opioid inhibition of morphine and cocaine self-administration in rats
    Glick, SD; Maisonneuve, IM; Raucci, AS
  • Possible pharmacotherapy of the opioid kappa receptor agonist for drug dependence
    Hasabe, K; Kawai, K; Suzuki, T; Kawamura, K; Tanaka, T; Narita, M
  • Simultaneous determination of circadian rhythms of locomotor activity and body temperature in the rat
    Honma, K; Hiroshige, T
  • Self-administration and behavioral economics of second-generation synthetic cathinones in male rats
    Huskinson, SL; Naylor, JE; Townsend, EA; Rowlett, JK; Blough, BE; Freeman, KB
  • Nalfurafine hydrochloride to treat pruritus: a review
    Inui, S
  • The emerging therapeutic roles of kappa-opioid agonists
    Jones, MR; Kaye, AD; Kaye, AJ; Urman, RD
  • Effects of atypical kappa-opioid receptor agonists on intrathecal morphine-induced itch and analgesia in primates
    Ko, MC; Husbands, SM
  • Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a phase III, randomized, double-blind, placebo-controlled study
    Kumagai, H; Ebata, T; Takamori, K; Muramatsu, T; Nakamoto, H; Suzuki, H
  • Efficacy and safety of a novel ĸ-agonist for managing intractable pruritus in dialysis patients
    Kumagai, H; Ebata, T; Takamori, K; Miyasato, K; Muramatsu, T; Nakamoto, H
  • Kappa-opioid receptor agonist U50,488H modulates cocaine and morphine self-administration in drug naïve rats and mice
    Kuzmin, AV; Semenova, S; Gerrits, MA; Zvartau, EE; Van Ree, JM
  • Ventilation measured by body plethysmography in hibernating mammals and in poikitotherms
    Milan, A
  • Kappa-opioid receptors and analgesia
    Millan, MJ
  • Effects of a newly synthesized kappa opioid receptor agonist, TRK-820, on the discriminative stimulus and rewarding effects of cocaine in rats
    Mori, T; Nomura, M; Nagase, H; Narita, M; Suzuki, T
  • Preclinical assessment of candidate analgesic drugs: recent advancements and future challenges
    Negus, SS; Vanderah, TW; Brandt, MR; Bilsky, EJ; Becerra, L; Borsook, D
  • Mu/kappa opioid interactions in rhesus monkeys: implications for analgesia and abuse liability
    Negus, SS; Schrode, K; Stevenson, GW
  • Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor
    Schattaurer, SS; Kuhar, JR; Song, A; Chavkin, C
  • Differential roles of opioid receptors in respiration, respiratory disease, and opiate-induced respiratory depression
    Shook, JE; Watkins, WD; Camporesi, EM
  • Drug synergism and dose-effect data analysis
    Tallarida, RJ
  • Revisiting the isobole and related quantitative methods for assessing drug synergism
    Tallarida, RJ
  • Reduced cocaine self-administration in muscarinic M5 acetylcholine receptor-deficient mice
    Thomsen, M; Woldbye, D; Wortwein, G; Fink-Jensen, A; Wess, J; Caine, SB
  • Corn oil, but not cocaine, is a more effective reinforcer in obese than in lean Zucker rats
    Townsend, EA; Beloate, LN; Huskinson, SL; Roma, PG; Freeman, KB
  • One year long-term study on the abuse-liability of nalfurafine in hemodialysis patients
    Ueno, Y; Mori, A; Yanagita, T